Intellia Therapeutics (NASDAQ:NTLA) PT Lowered to $88.00 at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA) had its target price reduced by Chardan Capital from $94.00 to $88.00 in a research note released on Thursday, Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also weighed in on NTLA. JPMorgan Chase & Co. decreased their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Evercore ISI raised Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a report on Thursday, September 19th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 target price on shares of Intellia Therapeutics in a report on Thursday, June 27th. Finally, StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $59.13.

Intellia Therapeutics Trading Up 0.6 %

Shares of NTLA opened at $15.95 on Thursday. The firm has a market cap of $1.62 billion, a P/E ratio of -2.91 and a beta of 1.76. Intellia Therapeutics has a 12 month low of $15.35 and a 12 month high of $34.87. The stock’s 50 day moving average is $20.71 and its two-hundred day moving average is $22.73.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $19.68 million. The business’s quarterly revenue was down 48.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.40) earnings per share. Equities research analysts forecast that Intellia Therapeutics will post -5.22 EPS for the current year.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Intellia Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock worth $254,514,000 after acquiring an additional 155,579 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Intellia Therapeutics by 209.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,561 shares of the company’s stock valued at $322,000 after purchasing an additional 7,151 shares during the period. SteelPeak Wealth LLC acquired a new position in shares of Intellia Therapeutics in the first quarter valued at approximately $229,000. Allspring Global Investments Holdings LLC increased its stake in Intellia Therapeutics by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock worth $245,000 after buying an additional 750 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in Intellia Therapeutics by 6.2% during the 1st quarter. Commonwealth Equity Services LLC now owns 34,593 shares of the company’s stock worth $952,000 after buying an additional 2,034 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.